Rollin M Gallagher. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Consumer Product Safety/legislation & jurisprudenceConsumer Product Safety/standardsCyclooxygenase Inhibitors/adverse effectsCyclooxygenase Inhibitors/therapeutic useDrug Industry/economicsDrug Industry/legislation & jurisprudenceDrug Industry/trendsDrug and Narcotic Control/economicsDrug and Narcotic Control/legislation & jurisprudenceDrug and Narcotic Control/trendsHumansLactones/adverse effectsLactones/therapeutic usePain/drug therapyPain/prevention & controlPreoperative Care/trendsRisk Assessment/economicsRisk Assessment/standardsSulfones/adverse effectsSulfones/therapeutic use
Substances： See more » Cyclooxygenase InhibitorsLactonesSulfonesrofecoxib
Year: 2004 PMID： 15563316 DOI： 10.1111/j.1526-4637.2004.04056.x
Source DB: PubMed Journal: Pain Med ISSN： 1526-2375 Impact factor: 3.750